Table 3.
Complement activation products in multiple sclerosis disease subgroups and controls.
| Bb mg/l |
C4a mg/l |
p | p* | |||||
|---|---|---|---|---|---|---|---|---|
| No. | Mean | SD | No. | Mean | SD | |||
| Control | 35 | 1.04 | 0.21 | 35 | 819.65 | 570.94 | N/A | <0.001 |
| Total MS | 82 | 1.07 | 0.30 | 176 | 1477.27 | 941.15 | <0.001 | N/A |
| S-RRMS | 20 | 1.03 | 0.32 | 37 | 1180.66 | 784.56 | 1.000 | 0.011 |
| A-RRMS | 20 | 0.98 | 0.19 | 68 | 1692.26 | 1080.47 | <0.001 | N/A |
| SPMS | 22 | 1.14 | 0.31 | 34 | 1288.56 | 736.92 | 0.316 | 0.190 |
| PPMS | 20 | 1.31 | 0.42 | 37 | 1579.80 | 646.69 | 0.154 | 1.000 |
SD, standard deviation p-values are measured using students t-test to compare MS and controls and ANOVA for multiple comparisons. p-values are shown for the subgroup analysis if a significant difference was seen at ANOVA. p = comparison with control group. p* = comparison with A-RRMS group. S-RRMS, stable relapsing–remitting MS with no relapses reported for at least 12 months; A-RRMS, acute relapsing–remitting MS sampled in relapse; SPMS, secondary progressive MS; PPMS, primary progressive MS.